CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- FinancialsAltman Z-Score 2.74: safe zone
- Interpretations5 currently firing — 5
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.82%Below 5Y avg (0.84%)
Annual Rate
CNY 0.10Paid annual
Payout Ratio
32.3%Sustainable
Last Ex-Dividend
May 29, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.21BCNY477.12M · vs all stocks (USD)
Trailing P/E
40.10xvs Biotechnology peers
Revenue (TTM)
1.40BCNY208.34M · vs all stocks (USD)
Profit Margin
5.58%vs Biotechnology peers
Beta
0.3650xvs all stocks
52-Week Change
-19.35%vs all stocks
Market Capitalization
3.21BCNY477.12M · vs all stocks (USD)
Enterprise Value
3.82BCNY568.04M · vs all stocks (USD)
Trailing P/E
40.10xvs Biotechnology peers
Forward P/E
33.11xvs Biotechnology peers
Price to Sales (TTM)
2.24xvs Biotechnology peers
Price to Book (MRQ)
1.75xvs Biotechnology peers
Enterprise to Revenue
2.73xvs Biotechnology peers
Enterprise to EBITDA
18.63xvs Biotechnology peers
Gross Margin
44.23%vs Biotechnology peers
Profit Margin
5.58%vs Biotechnology peers
Operating Margin
8.26%vs Biotechnology peers
Return on Assets (TTM)
1.80%vs Biotechnology peers
Return on Equity (TTM)
5.59%vs Biotechnology peers
Revenue (TTM)
1.40BCNY208.34M · vs all stocks (USD)
Revenue per Share (TTM)
5.53CNYUpdated Aug 21, 2026Quarterly Revenue Growth
11.20%vs Biotechnology peers
Gross Profit (TTM)
620.45MCNY92.27M · vs all stocks (USD)
EBITDA (TTM)
128.19MCNY19.06M · vs all stocks (USD)
Net Income (TTM)
78.10MCNY11.61M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
86.60%vs Biotechnology peers
Operating Cash Flow (TTM)
124.59MCNY18.53M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
16.51MCNY2.46M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.1000CNYUpdated Aug 21, 2026Trailing Annual Dividend Yield
0.82%vs all stocks
5-Year Average Dividend Yield
0.84%vs all stocks
Payout Ratio
32.26%vs Biotechnology peers
Minority Interest (Equity)
128.20MCNYFY2025 · Dec 31, 2025Revenue
1.37BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
754.15MCNYFY2025 · Dec 31, 2025Gross Profit
611.97MCNYFY2025 · Dec 31, 2025Operating Income
134.07MCNY19.94M · vs all stocks (USD)
Pre-tax Income
123.71MCNYFY2025 · Dec 31, 2025Income Tax Expense
26.24MCNYFY2025 · Dec 31, 2025Net Income
97.47MCNYFY2025 · Dec 31, 2025EBIT
141.70MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
245.48MCNYFY2025 · Dec 31, 2025Research & Development
139.21MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
183.63MCNYFY2025 · Dec 31, 2025Other Operating Expenses
15.75MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
761.34KCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
18.00MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.2800CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.2800CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
249.32MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
249.32MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
97.47MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-27.66MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
19.01MCNYFY2025 · Dec 31, 2025Free Cash Flow
-60.75MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
235.04MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
97.47MCNYFY2025 · Dec 31, 2025Other Non-cash Items
19.67MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-47.54MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-50.59MCNYFY2025 · Dec 31, 2025Capital Expenditures
-79.75MCNYFY2025 · Dec 31, 2025Net Acquisitions
-1.31MCNYFY2025 · Dec 31, 2025Purchase of Investments
-437.50KCNYFY2025 · Dec 31, 2025Sale of Investments
6.72MCNYFY2025 · Dec 31, 2025Other Investing Activity
188.04KCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-74.59MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
752.99MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-716.04MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-43.01MCNYFY2025 · Dec 31, 2025Other Financing Charges
1.73MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-4.33MCNYFY2025 · Dec 31, 2025Shares Outstanding
253.03MSharesUpdated Aug 21, 2026Float Shares
90.03MSharesUpdated Aug 21, 2026% Held by Insiders
65.74%vs all stocks
% Held by Institutions
2.38%vs all stocks
Total Cash (MRQ)
497.38MCNY73.97M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.97CNYUpdated Aug 21, 2026Total Debt (MRQ)
696.51MCNY103.58M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.3616xvs Biotechnology peers
Current Ratio (MRQ)
1.19xvs Biotechnology peers
Book Value per Share (MRQ)
7.11CNYUpdated Aug 21, 2026Total Assets
3.04BCNY452.03M · vs all stocks (USD)
Total Current Assets
1.18BCNYFY2025 · Dec 31, 2025Total Liabilities
1.13BCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.86BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
121.85MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.01BCNYFY2025 · Dec 31, 2025Cash
235.04MCNYFY2025 · Dec 31, 2025Cash Equivalents
9.12MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
244.16MCNYFY2025 · Dec 31, 2025Other Short-term Investments
224.87MCNYFY2025 · Dec 31, 2025Accounts Receivable
379.02MCNYFY2025 · Dec 31, 2025Inventory
226.37MCNYFY2025 · Dec 31, 2025Accounts Payable
194.41MCNYFY2025 · Dec 31, 2025Short-term Debt
618.99MCNYFY2025 · Dec 31, 2025Other Current Liabilities
14.87MCNYFY2025 · Dec 31, 2025Long-term Debt
59.79MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
1.11MCNYFY2025 · Dec 31, 2025Common Stock (Book)
253.03MCNYFY2025 · Dec 31, 2025Retained Earnings
780.65MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.91BCNY284.14M · vs all stocks (USD)
52-Week Low
10.68CNYUpdated Aug 21, 202652-Week High
18.41CNYUpdated Aug 21, 202652-Week Change
-19.35%vs all stocks
Beta
0.3650xvs all stocks
50-Day MA
11.94CNYUpdated Aug 21, 2026200-Day MA
14.21CNYUpdated Aug 21, 2026Avg 10-Day Volume
6.26MSharesUpdated Aug 21, 2026Avg 30-Day Volume
4.24MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
0.3100CNYUpdated Aug 21, 20265 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
How is this stock valued?
Price Below Mean With Profitability And Book Value
Price sits well below its yearly mean, on three profitable years and rising book value.
Reads
Price Below Mean With Profitability And Equity
Price sits well below its yearly mean, profitable three years, and its equity ratio is high for its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.44Profit Margin: 0.06
Financial Health
Altman Z-Score 2.74: safe zoneNotable
Altman Z-Score: 2.74
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Orthofix Medical Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Baolingbao Biology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlow
Yungshin Global Holding Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Anhui Fengyuan Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shaanxi Panlong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Guangdong VTR Bio-Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlow
Huaren Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Ever Supreme Bio Technology Co., Ltd
Tier 1ProductionApproval-Gated PipelineRuleFlow
Daewoong Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Honz Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Xiamen Amoytop Biotech Co., Ltd.
5 interpretationsRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital ElevatedPrice Below Mean With Profitability And Book ValuePrice Below Mean With Profitability And Equity
Lubair Aviation Technology
5 interpretationsRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital ElevatedPrice Below Mean With Profitability And Book ValuePrice Below Mean With Profitability And Equity
Tibet Huayu Mining Co., Ltd.
4 interpretationsRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthPrice Below Mean With Profitability And Book ValuePrice Below Mean With Profitability And Equity